Literature DB >> 29027994

Bone diseases: Romosozumab - on track or derailed?

Sundeep Khosla1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29027994      PMCID： PMC7176335          DOI： 10.1038/nrendo.2017.136

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

Review 1.  Osteoporosis treatment: recent developments and ongoing challenges.

Authors:  Sundeep Khosla; Lorenz C Hofbauer
Journal:  Lancet Diabetes Endocrinol       Date:  2017-07-07       Impact factor: 32.069

2.  Romosozumab - Promising or Practice Changing?

Authors:  Clifford J Rosen
Journal:  N Engl J Med       Date:  2017-09-11       Impact factor: 91.245

3.  Romosozumab in postmenopausal women with low bone mineral density.

Authors:  Michael R McClung; Andreas Grauer; Steven Boonen; Michael A Bolognese; Jacques P Brown; Adolfo Diez-Perez; Bente L Langdahl; Jean-Yves Reginster; Jose R Zanchetta; Scott M Wasserman; Leonid Katz; Judy Maddox; Yu-Ching Yang; Cesar Libanati; Henry G Bone
Journal:  N Engl J Med       Date:  2014-01-01       Impact factor: 91.245

4.  Romosozumab Treatment in Postmenopausal Women with Osteoporosis.

Authors:  Felicia Cosman; Daria B Crittenden; Jonathan D Adachi; Neil Binkley; Edward Czerwinski; Serge Ferrari; Lorenz C Hofbauer; Edith Lau; E Michael Lewiecki; Akimitsu Miyauchi; Cristiano A F Zerbini; Cassandra E Milmont; Li Chen; Judy Maddox; Paul D Meisner; Cesar Libanati; Andreas Grauer
Journal:  N Engl J Med       Date:  2016-09-18       Impact factor: 91.245

5.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.

Authors:  M E Brunkow; J C Gardner; J Van Ness; B W Paeper; B R Kovacevich; S Proll; J E Skonier; L Zhao; P J Sabo; Y Fu; R S Alisch; L Gillett; T Colbert; P Tacconi; D Galas; H Hamersma; P Beighton; J Mulligan
Journal:  Am J Hum Genet       Date:  2001-02-09       Impact factor: 11.025

6.  Relationship between osteoporosis and cardiovascular disease in postmenopausal women.

Authors:  László B Tankó; Claus Christiansen; David A Cox; Mary Jane Geiger; Michelle A McNabb; Steven R Cummings
Journal:  J Bone Miner Res       Date:  2005-07-18       Impact factor: 6.741

Review 7.  Wnt signaling in cardiovascular disease: opportunities and challenges.

Authors:  Austin Gay; Dwight A Towler
Journal:  Curr Opin Lipidol       Date:  2017-10       Impact factor: 4.776

8.  Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.

Authors:  Xiaodong Li; Michael S Ominsky; Kelly S Warmington; Sean Morony; Jianhua Gong; Jin Cao; Yongming Gao; Victoria Shalhoub; Barbara Tipton; Raj Haldankar; Qing Chen; Aaron Winters; Tom Boone; Zhaopo Geng; Qing-Tian Niu; Hua Zhu Ke; Paul J Kostenuik; W Scott Simonet; David L Lacey; Chris Paszty
Journal:  J Bone Miner Res       Date:  2009-04       Impact factor: 6.741

9.  Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.

Authors:  Kenneth G Saag; Jeffrey Petersen; Maria Luisa Brandi; Andrew C Karaplis; Mattias Lorentzon; Thierry Thomas; Judy Maddox; Michelle Fan; Paul D Meisner; Andreas Grauer
Journal:  N Engl J Med       Date:  2017-09-11       Impact factor: 91.245

Review 10.  Building bone to reverse osteoporosis and repair fractures.

Authors:  Sundeep Khosla; Jennifer J Westendorf; Merry Jo Oursler
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808
  10 in total
  7 in total

Review 1.  Inhibiting Cellular Senescence: A New Therapeutic Paradigm for Age-Related Osteoporosis.

Authors:  Sundeep Khosla; Joshua N Farr; James L Kirkland
Journal:  J Clin Endocrinol Metab       Date:  2018-04-01       Impact factor: 5.958

2.  Cellular senescence in bone.

Authors:  Joshua N Farr; Sundeep Khosla
Journal:  Bone       Date:  2019-01-16       Impact factor: 4.398

Review 3.  Sclerostin: From Molecule to Clinical Biomarker.

Authors:  Ahmed Omran; Diana Atanasova; Filip Landgren; Per Magnusson
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

4.  NOTUM inhibition increases endocortical bone formation and bone strength.

Authors:  Robert Brommage; Jeff Liu; Peter Vogel; Faika Mseeh; Andrea Y Thompson; David G Potter; Melanie K Shadoan; Gwenn M Hansen; Sabrina Jeter-Jones; Jie Cui; Dawn Bright; Jennifer P Bardenhagen; Deon D Doree; Sofia Movérare-Skrtic; Karin H Nilsson; Petra Henning; Ulf H Lerner; Claes Ohlsson; Arthur T Sands; James E Tarver; David R Powell; Brian Zambrowicz; Qingyun Liu
Journal:  Bone Res       Date:  2019-01-08       Impact factor: 13.567

Review 5.  Sclerostin and Vascular Pathophysiology.

Authors:  Antonino Catalano; Federica Bellone; Nunziata Morabito; Francesco Corica
Journal:  Int J Mol Sci       Date:  2020-07-06       Impact factor: 5.923

6.  Shuxuetong injection simultaneously ameliorates dexamethasone-driven vascular calcification and osteoporosis.

Authors:  Zhe Xu; Xiaoguang Liu; Yanqing Li; Hongliang Gao; Tao He; Chunlei Zhang; Wei Hao; Xu Teng
Journal:  Exp Ther Med       Date:  2021-01-08       Impact factor: 2.447

Review 7.  A Roadmap to Gene Discoveries and Novel Therapies in Monogenic Low and High Bone Mass Disorders.

Authors:  Melissa M Formosa; Dylan J M Bergen; Celia L Gregson; Antonio Maurizi; Anders Kämpe; Natalia Garcia-Giralt; Wei Zhou; Daniel Grinberg; Diana Ovejero Crespo; M Carola Zillikens; Graham R Williams; J H Duncan Bassett; Maria Luisa Brandi; Luca Sangiorgi; Susanna Balcells; Wolfgang Högler; Wim Van Hul; Outi Mäkitie
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-13       Impact factor: 5.555
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.